AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04625842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focus group interview
Description: Group interview with patients who received radiation treatment
Study NCT01444742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction:~10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)~Consolidation:~10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)
Study NCT01444742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction:~20 mg subcutaneously twice daily for 7 days (days 1-7)~Consolidation:~20 mg subcutaneously twice daily for 5 days (days 1-5)
Study NCT01163812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic D2 distal gastrectomy
Description: Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved.
Study NCT03138187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Description: The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
Study NCT03138187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous exercise
Description: The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
Study NCT01715753 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: > 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
Study NCT01715753 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet counseling and group education lessons
Description: Individual and group diet counseling to achieve a >10% weight loss
Study NCT04603885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Description: A randomized controlled trial will be used to test the feasibility of a home-based exercise program to improve BDNF DNA demethylation among individuals with T2DM. A total of 42 participants will be randomized 2:1 to receive aerobic exercise intervention (n=28) or attention control (n=14) for 3 months. This ratio is used to offset an anticipated attrition imbalance across groups.
Study NCT04603885 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching exercise
Description: stretching exercise
Study NCT04457180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Apatinib will be administered daily from on D5 through D16
Study NCT04457180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide
Description: Repaglinide will be administered daily on D1 and D12
Study NCT04457180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be administered daily on D2 and D13
Study NCT03171844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin to skin
Description: 3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
Study NCT03399981 — intervention group
Intervention type: BIOLOGICAL
Intervention: Tysabri
Description: Administered as specified in the treatment arm.
Study NCT01713842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCZ
Description: Tocilizumab at week 0, 4 and 8.
Study NCT00314626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: Efavirenz
Study NCT00314626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir+lamivudine
Description: Abacavir+lamivudine
Study NCT03819062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: A 3 week treatment period with 8 treatment sessions in total.
Study NCT03211221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
Study NCT03211221 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies \< or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
Study NCT03714321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation (MIE)
Description: Randomization of 30 patients, 15 in each arm, to receive either CPAP or MIE.
Study NCT00955812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPB-31121
Description: 50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
Study NCT03174418 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary angiography and optical coherence tomography
Description: Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
Study NCT03821818 — intervention group
Intervention type: BEHAVIORAL
Intervention: Food Allergy Elimination + Willis Exercise
Description: Food Allergy Elimination + Willis Exercise (performing a 2-minute Aerobic-surge exercise > 75% max heart rate, 5/day)
Study NCT03347981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of hydrophobic material
Study NCT03347981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation active comparator
Description: Implantation of trifocal IOL POD F consisting of hydrophilic material
Study NCT03179891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam Buccal Film 12.5 mg
Description: All subjects received a single dose of DBF 12.5 mg during the interictal state and during the ictal/peri-ictal state with at least 14 days washout between the 2 treatment periods
Study NCT01512602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DBT
Description: 16 weeks DBT treatment
Study NCT01512602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAMS
Description: CAMS-informed psychotherapy
Study NCT03487809 — intervention group
Intervention type: DRUG
Intervention: Budesonide/Cisclesonide
Description: One arm observation study: Duasma 1 puff bid (Budesonide 200mcg bid) or Alvesco 1 puff qd (Ciclesonide 160mcg qd) for participants aged 11 years and younger, Duasma 2 puffs bid (Budesonide 400mcg bid) or Alvesco 1 puff bid(Ciclesonide 160mcg bid) for participants aged 12 years and older
Study NCT02607592 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin and pemetrexed
Description: cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
Study NCT02607592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin+pemetrexed
Description: nedaplatin 90mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
Study NCT03198520 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Solvay Dental 360™
Description: polymer Removable Partial Denture (RPD)
Study NCT01688128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase I U-SMART (4 wks)
Description: Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
Study NCT01688128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Washout (2 wks)
Description: 2-weeks wash out period in both arms
Study NCT01688128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phase II U-SMART (4 wks)
Description: Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
Study NCT01141114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient navigation
Description: Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
Study NCT01141114 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT00761852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruboxistaurin
Description: 32 mg daily for 2 weeks
Study NCT00761852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tab po QD for 2 weeks
Study NCT04301232 — intervention group
Intervention type: OTHER
Intervention: Modified Aldrete Scoring System (mASS)
Description: Activity( Moves all extremities, Moves two extremities, Unable to move extremities), Respiration( Breathes deeply, coughs freely, Dyspneic, shallow or limited breathing, Apneic), Circulation (blood pressure) ( 20 mm Hg > preanesthetic level, 20 - 50 mm Hg > preanesthetic level, 50 mm Hg > preanesthetic level), Consciousness (Fully awake, Arousable on calling, Not responding), Oxygen saturation( SpO2 > 92% on room air, Supplemental O2 required to maintain SpO2 > 90%,SpO2 \< 90% with O2 supplementation), scoring is done as 2,1,0, respectively. A score of 9 or more would be required for a patient after general anesthesia for discharge
Study NCT04301232 — intervention group
Intervention type: OTHER
Intervention: White's Fast-Track Scoring System (WFTSS)
Description: Physical activity (Able to move all extremities on command, ,Some weakness in movement of extremities, Unable to voluntarily move extremities),Respiratory stability(Able to breathe deeply,Tachypnea,Dyspneic),Hemodynamic stability; (Blood pressure(MAP)\<15%, Blood pressure 15-30%, Blood pressure>30%, Level of consciousness,(Awake\&orientated Arousable with minimal stimulation, Responsive only to tactile stimulation),Oxygen saturation status(Maintains value>90% on room air, Requires supplemental oxygen, Saturation\<90% with supplemental oxygen), Postoperative pain assessment(None or mild discomfort, Moderate to severe pain controlled with analgesics, Persistent severe pain), Postoperative emetic symptoms(None or mild nausea w/no active vomiting, Transient vomiting or retching, Persistent moderate to severe nausea\&vomiting), Scoring is done as 2,1,0, respectively. A minimal score of 12(with no score\<1 in any individual category)would be required for a patient after general anesthesia
Study NCT04301232 — intervention group
Intervention type: OTHER
Intervention: SPEEDS criteria
Description: Extremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and \< 180, HR > 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in roExtremity movement (moves all four) Y/N, Stable vital signs( SBP > 90 and \< 180, HR > 50 and \< 110) Y/N, Dialogue (oriented person/place) Y/N, Oxygen saturation >90% in room air Y/N, Pain Control (VAS \< 4) Y/N, Emesis Control Y/N. A patient must have a response of yes to all parameters to progress to phase II recovery
Study NCT04095780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced oral hygiene care programme
Description: 1. Brush teeth with standardized power tooth brush twice a day.~2. Rinse mouth with chlorhexidine twice a day.~3. Oral hygiene education
Study NCT04095780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: Oral hygiene education
Study NCT04431336 — intervention group
Intervention type: BEHAVIORAL
Intervention: movement
Description: movement
Study NCT03076931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microlaryngoscopy
Description: Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
Study NCT03076931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voice Evaluation
Description: Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
Study NCT03076931 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway Reconstruction
Description: This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
Study NCT00917527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Study NCT00917527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
Study NCT02556996 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETEC/rCTB vaccine
Description: Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10\^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
Study NCT02556996 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10\^11 heat-killed bacteria per dose)
Study NCT02931136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Huperzine A
Description: The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
Study NCT02931136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will treatment by the placebo in 52 weeks.
Study NCT04427683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindful parenting program
Description: Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
Study NCT04427683 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief mindful parenting program
Description: Mindfulness exercise include formal and informal mindfulness exercises, and additional exercise for coping with anger and arousing emotions. Psychoeducation includes understanding relationship between thoughts and feelings, fight or flight responses and adaptive coping in parenting relationship.
Study NCT00029913 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Observation of participants who received HIV preventive vaccine and became infected.
Study NCT03589495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl L Cysteine
Description: 100 mg/kg n acetyl cysteine dissolved in dextrose5%
Study NCT03589495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dextrose 5%
Study NCT01460953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health literacy training video
Description: participants will watch a training video
Study NCT02274181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal
Study NCT03702751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive tape
Description: will be subjected to skin repair after episiotomy with skin adhesive tape.
Study NCT03702751 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous subcuticular skin suturing
Description: will be subjected to skin repair after episiotomy with the currently traditional method for episiotomy repair by continuous absorbable subcuticular suture.
Study NCT00006392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: 400 IU daily by mouth for 7-12 years
Study NCT00006392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenium
Description: 200 mcg daily for 7-12 years
Study NCT00006392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E placebo
Description: daily for 7-12 years
Study NCT00006392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E placebo
Description: daily for 7-12 years
Study NCT00006392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selenium placebo
Description: daily for 7-12 years
Study NCT00006392 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: selenium placebo
Description: daily for 7-12 years
Study NCT02131441 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic hepatectomy
Study NCT02131441 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: open liver resection
Study NCT03090087 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
Study NCT03090087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
Study NCT02902081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Study NCT02902081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01063387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer
Description: Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
Study NCT01063387 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer
Description: Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
Study NCT03633526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659/TEZ/IVA
Description: VX-659/TEZ/IVA FDC tablet.
Study NCT03633526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: IVA mono tablet.
Study NCT00943891 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsies
Study NCT02576444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
Study NCT02576444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
Study NCT02576444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: The recommended dose will be available no earlier than March 2016.
Study NCT02576444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: Patients will be administered AZD6738 at 160 mg daily for days 1-7 of a 28-day cycle (7/28) schedule. AZD6738 is available as 100, 20, and 10 mg tablets. Tablets should be taken daily.
Study NCT00492323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice daily for 4 weeks
Study NCT00492323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carisbamate
Description: 200 mg tablet twice daily for 4 weeks